Lipanor

Lipanor: an effective lipid-lowering agent for the control of cholesterol and triglycerides

Lipanor, also known as Ciprofibrate or Lipantil 200 M, is a pharmacological drug from the group of lipid-lowering drugs known as fibrates. It is used to control cholesterol and triglyceride levels in the body. Lipanor is manufactured in France by Sanofi Winthrop Industrie.

Lipanor is presented in the form of capsules containing 100 mg of the active substance - Ciprofibrate. This drug is indicated for use in endogenous hypercholesterolemia (isolated or associated) and hypertriglyceridemia that cannot be corrected by diet and physical activity. Its use is also recommended in case of presence of risk factors for hypercholesterolemia.

However, there are some contraindications to the use of Lipanor. It is not recommended in case of hypersensitivity to the drug, or in the presence of renal or liver failure. The use of Lipanor is also prohibited during pregnancy and breastfeeding. This drug is not intended for children.

Some side effects may occur when using Lipanor. These may include headaches, nausea, weakness, increased fatigue, myositis, myalgia, exacerbation of cholelithiasis, increased activity of serum transaminases, creatinine and skin allergic reactions.

It is necessary to pay attention to the interaction of Lipanor with other drugs. It is incompatible with hepatotoxic agents such as perexillite maleate and MAO inhibitors. In addition, Lipanor enhances the effect of indirect anticoagulants, such as antivitamins K. Nicotinic acid derivatives and other cholesterol-lowering drugs can increase the effectiveness of Lipanor.

There is no reliable data on an overdose of Lipanor. However, when using it, it is recommended to follow the prescribed dosage and doctor's instructions.

It is important to note special instructions for the use of Lipanor. If the drug is not effective after 3-6 months of use, combination therapy may be required. During treatment, careful monitoring of the level and activity of liver transaminases is necessary. If serum alanine aminotransferase (ALT) activity exceeds 100 units, Lipanor should be discontinued. You should also avoid drinking alcohol while taking Lipanor, as this may increase its hepatotoxic effect.

The excretory route for Lipanor is through bile, so its use in patients with impaired biliary excretion or cholelithiasis should be used with caution.

Overall, Lipanor is an effective lipid-lowering agent for controlling cholesterol and triglyceride levels. However, before you start using it, you should consult your doctor to evaluate the indications, contraindications and possible side effects, as well as to receive individual recommendations on dosage and duration of treatment.